Schonfeld Strategic Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Schonfeld Strategic Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-24,193	Closed	-$1.14M	–	2072
2024 Q3	$1.14M	Buy	+24,193	New	+$1.23M	0.01%	1119
2024 Q1	–	Sell	-17,228	Closed	-$1.08M	–	2119
2023 Q4	$1.08M	Buy	+17,228	New	+$952K	0.01%	1007
2022 Q4	–	Sell	-17,567	Closed	-$1.15M	–	2659
2022 Q3	$1.15M	Buy	+17,567	New	+$1.27M	0.01%	1176
2021 Q3	–	Sell	-10,271	Closed	-$1.66M	–	2205
2021 Q2	$1.66M	Buy	+10,271	New	+$1.25M	0.02%	773
2020 Q2	–	Sell	-8,600	Closed	-$365K	–	1288
2020 Q1	$365K	Buy	+8,600	New	+$444K	0.02%	681
2019 Q4	–	Sell	-26,420	Closed	-$1.08M	–	1313
2019 Q3	$1.08M	Buy	+26,420	New	+$1.26M	0.03%	452
2018 Q4	–	Sell	-13,700	Closed	-$607K	–	1086
2018 Q3	$607K	Buy	+13,700	New	+$717K	0.03%	538

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Schonfeld Strategic Advisors's CRSP Position: Q4 2024 in Review

Schonfeld Strategic Advisors sold out of CRISPR Therapeutics (CRSP) in Q4 2024, closing a stake of 24,193 shares — an estimated $1.14M sold.

Schonfeld Strategic Advisors first reported a position in CRSP in Q3 2018 and held it in 7 quarters. The position peaked at $1.66M in Q2 2021. 404 funds tracked by Wall St. Rank hold CRSP as of Q4 2024.

Schonfeld Strategic Advisors reported no remaining CRISPR Therapeutics position as of Q4 2024 after selling out during the quarter.
Schonfeld Strategic Advisors sold 24,193 CRISPR Therapeutics shares in Q4 2024, an estimated $1.14M.
Schonfeld Strategic Advisors first reported a position in CRISPR Therapeutics in Q3 2018 and held it in 7 quarters.
Schonfeld Strategic Advisors's CRISPR Therapeutics position peaked at $1.66M in Q2 2021.
404 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2024.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.